Last Updated: 16 Sep 2024
Executive Summary
Candel Therapeutics Inc. (CADL) is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer. The company's lead candidate, CT-0508, is a monoclonal antibody targeting the CD123 receptor expressed on acute myeloid leukemia (AML) cells. CADL has recently announced positive interim data from its Phase 1/2 clinical trial of CT-0508, showing promising efficacy and safety.
Company Overview
Candel Therapeutics was founded in 2017 and is headquartered in Needham, MA. The company's mission is to develop and commercialize innovative therapies that address unmet medical needs in cancer. CADL's pipeline includes several preclinical and clinical-stage programs targeting various hematologic and solid tumors.
Fundamental Analysis
Revenue: CADL reported revenue of $31,000 for the year ended December 2023. The company is still in the early stages of development and has yet to generate significant revenue.
Earnings: CADL reported a net loss of $34.7 million for the year ended December 2023. The company's operating expenses are primarily driven by research and development costs.
EBITDA: CADL's EBITDA was -$34.6 million for the year ended December 2023.
Book Value: CADL's book value per share was -$0.321 as of December 2023.
EPS: CADL reported a diluted EPS of -$1.70 for the year ended December 2023.
Technical Analysis
52-Week High: $14.30
52-Week Low: $0.66
50-Day Moving Average: $5.99
200-Day Moving Average: $4.531
Beta: -0.932
CADL's stock price has been volatile in recent months, reflecting the company's early-stage development status. The stock is currently trading below its 50-day and 200-day moving averages.
Short Term Outlook
In the short term, CADL's stock price is likely to be driven by clinical data updates and regulatory milestones. The company is expected to release additional data from its Phase 1/2 trial of CT-0508 in the coming months. Positive data could drive the stock price higher, while negative data could lead to a sell-off.
Long Term Outlook
Candel Therapeutics has the potential to be a major player in the cancer immunotherapy market. The company's lead candidate, CT-0508, has shown promising efficacy and safety in early clinical trials. If CT-0508 is successful in late-stage trials, it could be a major new treatment option for AML patients.
Analyst Recommendations
The current analyst consensus on CADL is "Buy." One analyst has a "Buy" rating, while no analysts have "Hold" or "Sell" ratings. The average analyst price target is $11.00.
Disclaimer:
This report is for informational purposes only and should not be considered investment advice. Investors should always conduct their own due diligence before making any investment decisions.
